{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:46:42Z","timestamp":1787755602924,"version":"build-2784847793"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011254"],"award-info":[{"award-number":["2023J011254"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young and Middle-aged Scientific Research Major Project of Fujian Provincial Health Commission","award":["2022ZQNZD009"],"award-info":[{"award-number":["2022ZQNZD009"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian province","award":["2023Y9412"],"award-info":[{"award-number":["2023Y9412"]}]},{"name":"Fujian Medical University Student Innovation and EntrepreneurshipTraining Project, China","award":["202410392008"],"award-info":[{"award-number":["202410392008"]}]},{"name":"Special Research Funds for Local Science and Technology Development Guided by Central Government","award":["2023L3020"],"award-info":[{"award-number":["2023L3020"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350126"],"award-info":[{"award-number":["82350126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2021QH1278"],"award-info":[{"award-number":["2021QH1278"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Immune-related adverse events(irAEs) are common among cancer patients receiving dual immune checkpoint inhibitors (ICI). Cardiac adverse events rank among the most severe categories of such reactions. This study aims to investigate the characteristics and influencing factors of cardiac adverse events associated with dual ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We collected data on cardiac adverse events associated to dual ICIs from the US Food and Drug Administration Adverse Event Reporting System database (FAERS), covering the period from the first quarter of 2015 to the fourth quarter of 2024. A disproportionality analysis was performed to assess the association between different dual ICIs and cardiac adverse events, and a comprehensive study was conducted to identify potential influencing factors. Cardiac adverse events accounted for 7.5% of all ICI adverse event reports in the FAERS database. Nivolumab plus ipilimumab was associated with the highest number of significant preferred term (PT) signals, while durvalumab plus tremelimumab had the highest percentage of life-threatening outcomes. The median onset time for cardiac adverse events following dual ICIs therapy was 32 days (IQR 15\u201377). Myositis and myasthenia gravis were the most commonly co-reported extracardiac conditions in myocarditis cases, whereas complete atrioventricular block and cardiogenic shock were the most frequently reported intracardiac complications. Older patients, males, and those with kidney cancer were at higher risk of developing cardiac adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified distinct associations between different dual ICIs treatment strategies and various cardiac adverse events. We further identified potential risk factors and co-reported symptoms of cardiotoxicity, which may aid in the early diagnosis and monitoring of ICI-associated cardiac adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag006","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:32:38Z","timestamp":1768912358000},"page":"108-117","source":"Crossref","is-referenced-by-count":6,"title":["Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-9742","authenticated-orcid":false,"given":"Huang","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Phase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuimei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Phase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zequn","family":"Sun","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Quan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Chemistry, Fuzhou University , Fuzhou 350108, Fujian Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1712-1657","authenticated-orcid":false,"given":"Huazhen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital , East Street, Fuzhou, Fujian Province 350000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Chemistry, Fuzhou University , Fuzhou 350108, Fujian Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9025-1721","authenticated-orcid":false,"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Cancer and Metabolism (Fujian Cancer Hospital) , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou, Fujian Province 350000 ,","place":["China"]},{"name":"Department of Chemistry, Fuzhou University , Fuzhou 350108, Fujian Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026022706312988600_pvag006-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3892\/ijo.2023.5534","article-title":"New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (review)","volume":"63","author":"Wang","year":"2023","journal-title":"Int J Oncol"},{"key":"2026022706312988600_pvag006-B2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1189\/jlb.5RI0116-013RR","article-title":"Combinatorial approach to cancer immunotherapy: strength in numbers","volume":"100","author":"Vilgelm","year":"2016","journal-title":"J Leukoc Biol"},{"key":"2026022706312988600_pvag006-B3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026022706312988600_pvag006-B4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026022706312988600_pvag006-B5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol"},{"key":"2026022706312988600_pvag006-B6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2026022706312988600_pvag006-B7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026022706312988600_pvag006-B8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026022706312988600_pvag006-B9","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"2026022706312988600_pvag006-B10","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026022706312988600_pvag006-B11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026022706312988600_pvag006-B12","doi-asserted-by":"crossref","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"2026022706312988600_pvag006-B13","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026022706312988600_pvag006-B14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","article-title":"Reporting of immune checkpoint inhibitor-associated myocarditis","volume":"392","author":"Al-Kindi","year":"2018","journal-title":"Lancet"},{"key":"2026022706312988600_pvag006-B15","doi-asserted-by":"crossref","first-page":"22199","DOI":"10.1038\/s41598-024-72864-4","article-title":"Clinical characteristics and influencing factors of anti-PD-1\/PD-l1-related severe cardiac adverse event: based on FAERS and TCGA databases","volume":"14","author":"Cheng","year":"2024","journal-title":"Sci Rep"},{"key":"2026022706312988600_pvag006-B16","doi-asserted-by":"crossref","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026022706312988600_pvag006-B17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf"},{"key":"2026022706312988600_pvag006-B18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026022706312988600_pvag006-B19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2026022706312988600_pvag006-B20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"2026022706312988600_pvag006-B21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022706312988600_pvag006-B22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026022706312988600_pvag006-B23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCMA.0000000000000910","article-title":"A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients","volume":"86","author":"Ho","year":"2023","journal-title":"J Chin Med Assoc"},{"key":"2026022706312988600_pvag006-B24","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1002\/cam4.5729","article-title":"Association between immune checkpoint inhibitors and myocardial infarction in asians: a population-based self-controlled case series","volume":"12","author":"Chan","year":"2023","journal-title":"Cancer Med"},{"key":"2026022706312988600_pvag006-B25","doi-asserted-by":"crossref","first-page":"e002545","DOI":"10.1136\/jitc-2021-002545","article-title":"Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach","volume":"9","author":"Heilbroner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026022706312988600_pvag006-B26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-022-02568-y","article-title":"Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States","volume":"42","author":"Yang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"2026022706312988600_pvag006-B27","doi-asserted-by":"crossref","first-page":"e16373","DOI":"10.1016\/j.heliyon.2023.e16373","article-title":"Cardiovascular events after the initiation of immune checkpoint inhibitors","volume":"9","author":"Suzuki","year":"2023","journal-title":"Heliyon"},{"key":"2026022706312988600_pvag006-B28","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026022706312988600_pvag006-B29","doi-asserted-by":"crossref","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: the impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2026022706312988600_pvag006-B30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/joim.20028","article-title":"Association among major adverse cardiovascular events with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"297","author":"Li","year":"2025","journal-title":"J Intern Med"},{"key":"2026022706312988600_pvag006-B31","first-page":"3","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger","year":"2022","journal-title":"Cardiooncology"},{"key":"2026022706312988600_pvag006-B32","first-page":"39","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated cardiovascular toxicities","volume":"38","author":"Wu","year":"2022","journal-title":"Acta Cardiol Sin"},{"key":"2026022706312988600_pvag006-B33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","author":"Salem","year":"2025","journal-title":"Eur Heart J"},{"key":"2026022706312988600_pvag006-B34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag006\/66521980\/pvag006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/108\/66521980\/pvag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/108\/66521980\/pvag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:31:43Z","timestamp":1772191903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/2\/108\/8435831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag006","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,22]]}}}